Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Haploidentical Stem Cell Selection using Miltenyi CliniMACS CD34 Reagent System in Treating Participants with High-Risk Hematologic Disorders

Trial Status: complete

This phase I/II trial studies the side effects and how well haploidentical stem cells selected using Miltenyi CliniMACS CD34 reagent system works in treating participants with high-risk hematologic disorders. Stem cells selected using Miltenyi CliniMACS CD34 reagent system from a half-matched donor, may increase the number of cells given to participants during stem cell transplantation in combination with umbilical cord blood transplantation.